Effect of patient-specific factors on weekly warfarin dose

Therapeutics and Clinical Risk Management

Volumn 3, Issue 3, 2007, Pages 499-504

  Whitley, Heather P ^a,d   Fermo, Joli D ^b   Chumney, Elinor C G ^b,c   Brzezinski, Walter Adam ^c  

^a AUBURN UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Department of Community and Rural Medicine ^*  (United States)

Author keywords

Anticoagulation; CYP450 inducers; Survey; Vitamin K; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; CARBAMAZEPINE; CYTOCHROME P450; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RIFAMPICIN; RITONAVIR; VITAMIN K GROUP; WARFARIN;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ANTICOAGULATION; ARTICLE; BODY HEIGHT; BODY WEIGHT; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CORRELATION COEFFICIENT; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG MEGADOSE; ETHNICITY; FEMALE; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PHARMACEUTICAL CARE; REGRESSION ANALYSIS; SEX DIFFERENCE; SMOKING; TRANSIENT ISCHEMIC ATTACK; VITAMIN INTAKE;

EID: 34547658151     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Ansell J, Hirsh J, Poller L, et al. 2004. The pharmacology and management of the vitamin K antagonists. Chest Guidelines: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines, 126:204S-233S.
2. Absher RK, Moore EM, Parker MH. 2002. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother, 36:1512-7.
3. Blann A, Hewitt J, Siddiqui F, et al. 1999. Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br J Haematol, 107:207-9.
4. Crowther MA, Ginsberg JB, Kearon C, et al. 1999. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med, 159:46-8.
5. Dang MN, Hambleton J, Kayser SR. 2005. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother, 39:1008-12.
6. Evans M, Lewis GM. 2005. Increase in international normalized ratio after smoking cessation in a patient receiving warfarin. Pharmacotherapy, 25:1656-1659.
7. Garcia D, Regan S, Crowther M, et al. 2005. Warfarin maintenance dosing patterns in clinical practice: Implications for safer anticoagulation in the elderly population. Chest, 137:2049-2056.
8. Gurwitz JH, Avorn J, Ross-Degnan D, et al. 1992. Aging and the anticoagulant response to warfarin therapy. Ann Int Med, 116:901-90.
9. Harrison L, Johnston M, Massicotte MP, et al. 1997. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med, 126:133-6.
10. Havrda DE, Mai T, Chonlahan J. 2005. Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. Pharmacotherapy, 25:303-307.
11. James AH, Britt RP, Raskino CL, et al. 1992. Factors affecting the maintenance dose of warfarin. J Clin Path, 45:704-706.
12. Merli GJ. 2005. Prevention of thrombosis with warfarin, aspirin, and mechanical methods. Clinical Cornerstone, 7:49-56.
13. Oates A, Jackson PR, Austin CA, et al. 1998. A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol, 46:157-161.
14. Rieder MJ, Reiner AP, Gage BF, et al. 2005. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 352:2285-93.
15. Sconce EA, Khan TI, Wynne HA, et al. 2005. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 106:2329-2333.
16. Singla DL, Morrill GB. 2005. Warfarin maintenance dosages in the very elderly. Am J Health-Syst Pharm, 62:1062-6.
17. Wittkowsky AK, Boccuzzi SJ, Wogen J, et al. 2004. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy, 24:1688-1674.